ProQR Therapeutics N.V. (PRQR) Stock Score, Valuation & Financial Research
ProQR Therapeutics N.V. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for PRQR
ProQR Therapeutics N.V. currently has a Wall Street Score of 25/100. The stored market price is $1.86. Its financial score is 14/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What ProQR Therapeutics N.V. does
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermor
PRQR financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $1.86
- Market capitalization:
- $195.9M
- Revenue:
- $15.4M
- Net income:
- $-52.0M
- Free cash flow:
- $-58.9M
- Cash:
- $92.4M
- Total debt:
- $15.6M
- EPS:
- -0.43
- Financial score:
- 14/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-58.9M, showing cash burn in the current stored period.
- The balance sheet shows $92.4M of cash versus $15.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 14/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PRQR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.